Q-omics provides the consensus-scored FAM222A profile across patient tissues and cancer cell-line models. FAM222A expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in SCLC. Among the 18 cancer types available for tumor–normal comparison, FAM222A is differentially expressed in 14, with the highest sampling consensus in KIRC. Additionally, FAM222A RNA expression shows 22,831 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight SCLC, KIRC, and GBM as cancer lineages where FAM222A shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for FAM222A — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes FAM222A survival associations across molecular data types. FAM222A RNA expression shows survival associations in the most cancer types (22), followed by mutation status (3) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible FAM222A RNA expression–survival associations across cancer types. High FAM222A expression shows unfavorable associations in MESO, but favorable associations in SCLC, HNSC, LGG, CESC and PAAD. The SCLC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify SCLC as the clearest survival context for FAM222A RNA expression.
This table summarizes FAM222A tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for FAM222A. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. FAM222A shows lower tumor expression in KIRC and KIRP and higher tumor expression in COAD, LIHC, UCEC and BRCA. The KIRC box plot shows higher FAM222A RNA expression in normal versus tumor tissue (log2 FC = −2.480, t-test p < 0.001).
This table shows molecular features associated with FAM222A in patient tissues and cancer cell lines. In patient samples, FAM222A shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, FAM222A RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Myeloma, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and BLOOD_Leukemia.
